BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Rhea-AI Summary
BriaCell (Nasdaq: BCTX) announced six clinical data items at the 2026 ASCO Annual Meeting (May 29–June 2, 2026): three poster presentations and three publication-only abstracts covering survival, quality of life, biomarkers, and cell‑based immunotherapy in metastatic breast cancer.
Poster sessions occur May 30 and June 1, 2026; ASCO will publish abstracts May 21, 2026 at 5:00 PM ET. Poster copies will be posted at https://briacell.com/scientific-publications/ after presentation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BCTX
On the day this news was published, BCTX gained 3.87%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | AACR QoL/biomarkers | Positive | -9.3% | Phase 3 QoL preservation and Phase 2 biomarker data in metastatic breast cancer. |
| Dec 18 | Nature Medicine feature | Positive | +3.2% | Phase 3 Bria-IMT trial highlighted among key 2026-shaping studies. |
| Dec 10 | SABCS 2025 data | Positive | -7.9% | Phase 2 survival benefit and Phase 3 biomarker/safety data across three posters. |
| Dec 09 | Phase 3 enrollment | Positive | -2.1% | Update that Phase 3 enrollment and interim OS analysis timing remain on track. |
| Dec 02 | SABCS preview | Positive | +3.7% | Announcement of upcoming SABCS posters with positive Phase 2 survival and Phase 3 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial and data presentations have often seen mixed-to-negative immediate price reactions despite generally positive clinical narratives.
Over the past six months, BriaCell has repeatedly highlighted progress in its Bria‑IMT metastatic breast cancer program and related biomarkers. Prior clinical-trial news, including SABCS® 2025 data, Nature Medicine recognition, and AACR 2026 quality-of-life/biomarker results, emphasized favorable safety, survival signals, and FDA Fast Track designation. Market reactions to these 5 clinical-trial updates averaged about -2.47%, with three negative and two positive moves, underscoring inconsistent short-term trading responses to otherwise constructive clinical milestones.
Historical Comparison
In the last five clinical-trial updates, BCTX moved an average of -2.47%, with three negative and two positive reactions, showing choppy trading around otherwise constructive data.
Recent clinical-trial news traces a path from Phase 2 survival signals and Phase 3 biomarker/safety updates at SABCS® 2025 through strong enrollment progress and recognition in Nature Medicine to AACR 2026 QoL and biomarker readouts, framing ASCO 2026 presentations as part of an ongoing Phase 3 maturation story for Bria‑IMT in metastatic breast cancer.
Regulatory & Risk Context
Key Terms
phase 2 medical
phase 3 medical
biomarker medical
progression-free survival medical
immunotherapy medical
liquid biopsy medical
pd-l1 medical
immune checkpoint inhibitors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented
- Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response
PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and publish-only abstracts are listed below.
Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
Abstract Title: Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 221
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
Session Type/Title: Poster Session - Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT
Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.
Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy.
Publication-Only Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors.
Presentation details will become available upon publication of the abstracts by ASCO on May 21, 2026 at 5:00 PM ET.
Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the presentation of three clinical data posters and three publication-only abstracts at the 2026 ASCO Annual Meeting and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
